Angiotensin-converting enzyme (ACE) is assumed to influence the activity of the hypothalamic-pituitary-adrenocortical (HPA) system, which shows hyperactivity in the majority of patients with major depression. The ACE gene, known to be associated with cardiovascular disorders, which in turn are accompanied with an increased susceptibility for depression, is therefore a promising candidate gene for affective disorders. We investigated the genetic association between 35 single-nucleotide polymorphisms (SNPs) and an insertion/deletion (I/D)-polymorphism in the ACE gene and the susceptibility for unipolar major depression together with the genetic association with ACE serum activity and functional parameters of the HPA system. Two independent case/control samples with a total of 843 unrelated unipolar depressed patients and 1479 healthy controls were investigated. A case/control sample was screened to detect genetic associations with unipolar major depression. In addition, a replication sample was used to confirm the detected associations and to further investigate functional consequences of the genetic variants associated with depression. In the screening sample, two SNPs within the ACE gene were significantly associated with unipolar major depression. The association with unipolar major depression of one SNP (rs4291) located in the promoter region of the ACE gene was confirmed in our replication sample. The T-allele of this SNP was associated with depression and depressed T-allele carriers showed higher ACE serum activity and HPA-axis hyperactivity. Variants of the ACE gene such as SNP rs4291 are suggested susceptibility factors for unipolar major depression. We could show that SNP rs4291 influences ACE activity and HPA-axis hyperactivity and might therefore represent a common pathophysiologic link for unipolar depression and cardiovascular disease.
Introduction
In recent years, evidence has emerged that genetic variants contribute to the multifactorial genesis of depressive disorders and influence therapeutic outcome. Angiotensin-converting enzyme (ACE) has been recognized as a major candidate gene for both, psychiatric and cardiovascular research. ACE is widely distributed in many tissues including the central nervous system (CNS). Its function comprises the hydrolysis of angiotensin I into angiotensin II (AT-II). Within the renin-angiotensin-cascade, AT-II is a potent vasopressor and aldosterone-stimulating peptide. ACE is expressed and colocalized in the CNS with substance P (SP)-containing neurons, primarily in basal ganglia and to a lesser extent in the hypothalamus and other brain regions. 1, 2 The ACE insertion/deletion (I/D)-polymorphism determines functional variants of the ACE gene with major impact on ACE plasma concentrations. 3, 4 The presence of the D-allele is associated with higher serum ACE activity. 4 In addition to its predominant effects on blood pressure regulation, in vitro studies in rodents (adult male Sprague-Dawley rats) showed that ACE also interferes with the secretion of pituitary hormones such as corticotropin (ACTH) and potentiates the stimulatory effects of corticotropin releasing hormone (CRH). 5 Dysregulation of the activity of the hypothalamic-pituitary-adrenocortical (HPA) system including elevated circulating plasma levels of both corticotropin (ACTH) and cortisol is one of the major neuroendocrine abnormalities observed in major depressive disorder (MDD). 6 The renin-angiotensin-system (RAS) 3 plays a modulatory role during stress-induced HPA-axis activation. In fact, the ACE I/D-polymorphism has been shown to exert a marked influence on HPA-axis hyperactivity in depressed patients 7 and seems to be related to both, the onset of action of antidepressant pharmacotherapies 8 and the stability of therapeutic response after partial sleep deprivation. 9 In contrast to biochemical and neuroendocrinological data that implicate ACE as a candidate gene for affective disorders, genetic association studies of the ACE I/D-polymorphism with major depression revealed divergent results. A significant association of the D-allele with affective disorders has been shown in a relatively small sample (n = 65), which included patients suffering from bipolar affective disorders or unipolar major depression. 10 However, a series of further association studies could not detect any interrelation between the ACE I/D-polymorphism and unipolar or bipolar depression. 8, 11, 12, 13 On the other hand, an association between the ACE I/D-polymorphism and an increased risk of myocardial infarction seems to be a rather consistent finding. 14 In order to examine systematically the role of ACE gene variants in the pathophysiology of major depression we investigated the association of 35 single-nucleotide polymorphisms (SNPs) and the ACE I/D-polymorphism within the ACE gene region covering all three ACE splice variants and the 5 0 and 3 0 neighboring genes in two ethnically homogeneous independent patient samples with major depression and two independent healthy control samples. We were then interested to investigate whether genetic variants of the ACE gene associated with unipolar major depression would also affect functional parameters such as ACE enzyme activity and HPA-axis activity. Moreover, in sample 1 we controlled for the presence of cardiovascular comorbidity as a potential confounder of an association with major depression, as ACE variants have been associated with an increased risk for coronary heart disease and coronary heart disease also predisposes to MDD and vice versa. 15 In sample 2, cardiovascular comorbidities were exclusion criteria for both the case and the control group.
Subjects and methods
We investigated a total of 843 unrelated in-patients suffering from unipolar major depression according to Diagnostic and Statistical Manual (DSM)-IV 16 and 1479 healthy controls. Sample 1 consisted of in-and outpatients at the Max-Planck Institute of Psychiatry in Munich (MPI) and two collaborating hospitals. The replication sample 2 consisted of in-patients of the Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich (LMU). Table 1 shows medical histories and demographic data for patients and controls. The study was approved by the local ethics committees. Written informed consent was obtained from all subjects.
Sample 1 (MPI)
In total, 642 patients with unipolar depression were recruited from in-patients at the MPI and psychiatric Ethnicity was recorded using a self-report sheet for perceived nationality, first language and ethnicity of the subject himself and all four grandparents. All included patients were Caucasian and 88% were of German origin.
Matched controls for sample 1
In total, 608 controls matched for ethnicity (using the same questionnaire as for patients), sex and age (to 5-year intervals) were recruited at the MPI (Table 1) . Controls were selected randomly from a Munichbased community sample and screened for the presence of anxiety and affective disorders using the Composite International Diagnostic Screener. 17 Only individuals negative for the above-named disorders were included in the sample. These subjects thus represent a group of healthy individuals with regard to depression and anxiety.
Assessment of medical comorbidities
The presence of 35 different medical, neurological and psychiatric disorders in all patients and healthy controls and their first-grade relatives was assessed using a self-report sheet. For this study, the presence of a heart attack or angina, a stroke, high blood pressure and high blood cholesterol in the patients and controls was recorded and used for statistical analysis.
Epidemiological control sample (e)
The Cooperative Health Research in the Augsburg Region (KORA) Survey 2000 studied a populationbased sample of 4261 subjects aged 25-74 years during 1999-2001. 18 The sampling design followed the guidelines of three previous surveys in the same region as part of the multinational WHO-MONICA (Monitoring Trends and Determinants of Cardiovascular Disease) study. For this study up to 626 KORA subjects (mean 49.2713.5 years, 45.5% male, 54.5% female) were genotyped for ACE polymorphisms. 18 
Sample 2 (LMU)
In total, 201 patients suffering from unipolar major depression were recruited from in-patients at the Department of Psychiatry and Psychotherapy of the LMU. Patients were diagnosed by experienced and trained psychiatrists according to DSM-IV using the Structured Clinical Interview for DSM-IV (SCID). Only patients of Caucasian origin from the same geographical area in southern Germany over 18 years old with an at least moderately severe depressive episode were included. The main inclusion criteria were unipolar depression and a score in the Hamilton Rating Scale for Depression 19 (17 item version, HAM-D17) of at least 18. 30.3% of the patients had a first episode and 69.7% a recurrent episode. Before inclusion in the study, blood samples were obtained for routine laboratory screening and a medical examination was performed to exclude severe medical disorders. Medical illness and the concomitant use of antihypertensive medication such as ACE inhibitors or angiotensin receptor blockers as well as hormone replacement therapies led to exclusion from the study. Patients were receiving various pharmacological and nonpharmacological treatments.
Matched controls for sample 2
In total, 245 age-and sex-matched controls of Caucasian ethnicity were recruited at the LMU and screened for psychiatric disorders (Structured Clinical Interview for DSM-IV) and familial loading (SADS Family History form) to exclude those with psychiatric disorders or first-degree affected members. To screen for psychological problems, personality traits were evaluated using the Minnesota Multiphasic Inventory 20 (MMPI), the Five Factor Inventory (FFI) 21 and the Temperament and Character Inventory (TCI). 22 Medical comorbidities were excluded as detailed for sample 2. This sample again represents a sample of healthy individuals with regards to psychiatric disorders, including mood disorders as well as medical morbidity.
DNA preparation sample 1 and matched controls On enrollment in the study, 40 ml of ethylenediamine-N,N,N 0 ,N 0 -tetraacetic acid (EDTA) blood were drawn from each patient and each healthy control. DNA was extracted from fresh blood using the Puregene whole blood DNA-extraction kit (Gentra Systems Inc., MN, USA).
DNA preparation sample 2 and matched controls DNA was isolated from 7.5 ml EDTA whole blood using the Invisorb Blood Giga Kit (Invitrogen, Berlin, Germany).
SNP genotyping
SNPs for ACE (NM_000789; NM_152830; NM_152831), CYB561 (NM_001915) and KCNH6 (NM_030779) were selected from dbSNP (http://www.ncbi.nlm.-nih.gov). SNP Ids, positions on UCSC genome built version hg16, heterozygosity and P-values for HardyWeinberg Equilibrium (HWE) in the sample are reported in Table 3 . The SNP search tool at http:// ihg.gsf.de/ihg/snps.html was used to download SNP sequences from public databases. To determine the overall distribution of the deviation from HWE in the healthy control group a set of 100 unlinked SNPs were genotyped. For each of these SNPs we calculated the P-value for a deviation from HWE (exact test for a deviation from HWE as implemented in the R package 'genetics'). In analogy to procedures performed for genomic controls we used the median of the P-values of these 100 tests as our parameter of interest. We also performed a simulation study drawing 10 000 replicates of 100 P-values distributed under the null-hypothesis and considered the distribution of the 10 000 medians of the P-values of the respective replicates. We found the 95% confidence interval (CI) for the median to be between 0.402 and 0.595, with the expected value to be 0.500, all values being in good keeping with theoretical expectations.
Genotyping was performed on a matrix-assisted laser desorption/ionization (MALDI)-TOF mass-spectrometer (MassArray system) employing the Spectrodesigner software (Sequenom, CA, USA) for primer selection and multiplexing, and the homogeneous mass-extension (hMe) process for producing primer extension products. 23 Genotyping was performed at the Genetics Research Centre GmbH, Munich, Germany. All primer sequences are available upon request.
ACE I/D-polymorphism genotyping
Genotyping of the I/D-polymorphism using polymerase chain reaction (PCR) amplification of the ACE I/ D-polymorphism was performed using the primers and methods described earlier. 7 A standard PCR was performed in a 25 ml PCR buffer (1.5 mM MgCl) containing 50 ng genomic DNA, 200 mM of each dNTP, 100 mM 7-deaza-guanosine 5 0 -triphosphate lithium salt (GTP), 1.25 U Ampli-Taq Gold DNA polymerase (Perkin-Elmer), 5% dimethylsulfoxide (DMSO) and 0.4 mM of the forward and reverse primers. This setting, which means that 7-deaza (GTP) and DSMO are included, was chosen to avoid mistyping of heterozygotes. 24 In a previous investigation with a control sample of 50 D/D-and 50 I/D-genotypes we compared this method with that proposed by Lindpaintner et al., 25 who applied a second, independent PCR amplification. Both settings identified heterozygotes with the same certainty. The insertion (I-allele) resulted in a product of 478 bp, deletion (D-allele) in 191 bp. All laboratory procedures and ratings were carried out under single-blind conditions: laboratory personnel were blinded to the origin of DNA probes and diagnoses, clinical raters were informed about the genotypes after discharge of the patients.
Performance of the combined Dex/CRH test and blood collection
The combined dexamethasone (Dex) suppression/ CRH test was performed in medication-free patients (sample 2) at the end of the first week after admission to hospital. Medication for sleep disturbances was restricted to chloralhydrate up to 1 g. The patients received 1.5 mg Dex (Fortecortin, Merck KG, Darmstadt, Germany) PO at 2300 hours on the day before the CRH challenge. At 1400 hours on the day of the CRH test an i.v. forearm catheter was inserted and the first blood samples collected, as described below. The patients had to remain supine on a bed in a single room under resting conditions. After a 60 min adaptation period baseline probes were acquired. At 1500 hours 100 mg human CRH lyophilisate (CRF human, Clinalfa AG, Läufelfingen, Switzerland) were injected within 30 s. Blood samples were collected at 15 min intervals until 1600 hours. 15 Blood sampling and CRH injection were performed using the 'through-the wall'-technique to avoid disturbing the patient.
ACE concentrations
Blood samples for determination of ACE activity were drawn in medication-free patients (sample 2) before the first application of antidepressant treatment and during steady-state conditions of antidepressant pharmacotherapy after 2 weeks of treatment. Serum for ACE determination was stored frozen at À801C until en bloc assessment. ACE was quantified using a commercial radio enzyme assay (REA) (ACE-REA, Diagnostic Products Corporation Biermann, Bad Nauheim, Germany). The lower detection limit was 3.8 U/l.
Serum cortisol determinations
Serum for cortisol determination was stored frozen at À801C until en bloc assessment. Cortisol was quantified using a commercial radioimmunoassay (RIA) (Cortisol-RIA, Diagnostic Products Corporation Biermann, Bad Nauheim, Germany). The lower detection limit was 8.28 nmol/l. Intra-and interassay coefficients of variation (CV) were 2.4 and 6.4%, respectively.
Statistical analysis
Mean differences in demographic and clinical variables between patients and controls were compared using Students t-tests and w 2 -tests. Analyses for case/control associations were performed calculating a logistic regression using R (version 1.8.1) and SPSS for Windows (Releases 11 and 12, SPSS Inc., Chicago, IL, USA) testing effects on the genotypic level. No associations on an allelic level were performed as deviation from HWE in one of the groups only allows for correct interpretation of genotypic associations. 26 Deviations from HWE were tested using the methodology developed in WittkeThompson et al. 27 for their compatibility with a genetic model for unipolar depression. Age and gender were used as covariates for all analyses. In sample 1 (MPI), heart attacks, stroke, high blood pressure or high blood cholesterol levels in the medical history were taken as additional covariates for SNP associations. Case/control associations were corrected for multiple testing using a Bonferroni-type correction. For the sample 1, the number of polymorphic, that is, informative SNPs was taken as the number of tests (N = 23). In the replication sample, the number of genotyped SNPs (N = 2) were taken as a correction factor.
For the analysis of the linkage disequilibrium (LD) pattern and haplotype block delineation we used haplotypes estimated by Haploview (http:// www.broad.mit.edu/personal/jcbarret/haplo/). Haplotype block definition was performed using the |D 0 | method 28 with a threshold of 0.85. Markers with minor allele frequency < 0.01 were ignored in this analysis.
LD between the ACE I/D-polymorphism, rs4291 and rs4295 was determined using the parameters D 0 and r 2 . 29 The effects of the SNP rs4291 genotypes on ACE concentration before and after antidepressant treatment and on combined Dex/CRH-tests after admission were investigated only in sample 2 (LMU) in order to rule out any possible influences of concomitant medical diseases and/or medication, which were not explicit exclusion criteria in sample 1 (MPI). ACE concentrations were investigated in 54 patients. The One-sample Kolmogorov-Smirnov test was used to test whether ACE enzyme activity was normally distributed. Mean differences in ACE concentrations between different genotypes were compared using a one-way analyses of variance (ANOVA) procedure. Combined Dex/CRH-tests were performed in 76 patients. To approach normality and homogeneity in the data hormonal concentrations were transformed with the log transformation before entering the analysis. To evaluate significant time effects on cortisol concentrations after hCRH injection and to compare cortisol plasma concentrations between different genotypes repeated measures (RM)-ANOVA with time as a within-subjects factor, genotype as a between-subjects factor and age and gender as covariates were performed. The level of significance was set at 0.05.
Results
Allele frequencies and haplotype block structure (sample 1) Thirty-five SNPs were genotyped in a region spanning 86 kb on chromosome 17q23 containing all three known splice variants of the ACE gene (NM_000789; NM_152830; NM_152831) and their two neighboring genes, CYB561 (NM_001915) 5 0 and KCNH6 (NM_030779) 3 0 . Of these, 23 turned out to be informative, leaving an average intermarker distance of informative SNPs of 3.8 kb (Table 3 ). Using genotype data from patients and controls from the unipolar depression study (sample 1), we constructed a LD block map based on D 0 using all SNPs with a heterozygosity over 1%. We detected 3 independent blocks of LD within the investigated region (Figure 1 Case/control association within sample 1 We found 11 SNPs to be associated with unipolar depression with a P-value < 0.05 ( Figure 2 ). The strongest associations were seen with rs4291 (P = 0.00077) and rs4295 (P = 0.0011), SNPs being located in the promoter region and first intron of the first ACE splice variant, respectively. The associations with these two SNPs were the only ones that remained significant after correcting for multiple testing ( Table 2 ). The homozygous T-allele of SNP rs4291 was associated with an enhanced risk for unipolar MDD (odds ratio (OR) = 1.91 (95% CI: 1.35-2.69)). The I/D-polymorphism showed only a trend (P < 0.1) for association.
Deviation from HWE
We separately calculated the P-value for the genotype distribution of these SNPs being in HWE for healthy controls and patients and observed that while there was no deviation from HWE in the patient group, a series of SNPs showed deviation from HWE in the healthy control group (Table 2) . These SNPs were concentrated in the promoter region of the ACE gene and identical with the SNPs showing the highest associations. SNPs in the neighboring genes of ACE or located more to the 3 0 end of ACE did not show any deviation from HWE in the healthy control group. A set of 100 unlinked SNP markers distributed over the genome genotyped in the control sample did not show any deviation from a normal distribution of HWE P-values. Their median P-value was 0.507, not significantly different from the expected value of 0.500, calculated using 10 000 simulations. In fact, this median P-value is slightly higher than expected, which, if anything, speaks against the hypothesis of a systemic deviation from HWE in this sample. We then regenotyped SNPs within the ACE locus in an epidemiological control sample. SNPs that showed a deviation from HWE in the healthy control group were in equilibrium in this sample; specifically rs4291 and rs4295 ( Table 2 ). The genotype frequencies of these SNPs were not significantly different from the patient group.
We then proceeded to test whether the observed deviation from HWE in the healthy control samples was compatible with a genetic model for the disease, as proposed by Wittke-Thompson et al. Based on the epidemiological data for the prevalence of the exclusion criteria for our selection criteria in controls, we estimated that about 43% of the general population was not eligible for inclusion in our healthy control samples. Using this figure and the genotype distributions given in Table 2 , the tests of goodness-of-fit were not significant for any of the associated SNPs for a recessive model in each case, the respective P-values were 0.066 (rs4291, sample 1), 0.072 (rs4291, sample 2) and finally 0.053 (rs4295, sample 1). Thus, our data are compatible with a recessive model for the mode of action of ACE on the susceptibility to unipolar depression. Influence of cardiovascular risk factors on the association with unipolar depression (sample 1) A history of a heart attack or angina, a stroke, high blood pressure or high blood cholesterol in depressed patients and controls was ascertained using a selfreport sheet. While we did not find any significant differences in the frequencies of heart attack or angina or elevated blood cholesterol between the two groups, depressed patients reported high blood pressure or a previous stroke significantly more often (Table 1) . We then tested whether the SNPs associated with unipolar depression were also associated with any of the medical parameters and found a significant association of rs4291 with the presence of a heart attack or angina (P < 0.05), and a trend for an association with rs4295 (P = 0.08). None of the other medical phenotypes showed an association with these SNPs. To rule out that the association of these SNPs with unipolar depression was due to stratification in these medical parameters we repeated the logistic regression analysis with the unipolar depression/control status as the dependent variable and included the presence of a heart attack or angina, stroke, high blood pressure or high blood cholesterol in addition to gender and age and rs4291 and rs4295 as covariates. Only the presence of high blood pressure, the genotype of rs4291 and the presence of stroke were included as significant independent contributors in this model ( Table 1) .
Replication of the case/control association within sample 2
The two significantly associated SNPs, rs4291 and rs4295, were genotyped in a second independent sample recruited at the LMU. The association with unipolar depression could be replicated in this sample for rs4291 but not rs4295 ( Table 2 ). The association of the SNP rs4291 T-allele with the risk of unipolar major depression could be replicated (OR = 2.88 (1.48-5.60)). The association did not improve when only patients with unipolar recurrent depression were analyzed.
ACE-I/D-polymorphism
In sample 1, we observed a trend for an association of the ACE I/D-polymorphism with unipolar depression (P = 0.084, Tables 2 and 3 While D 0 appears to be the better measure of population history, r 2 appears to be more useful in disease mapping. 29 Associations of functional parameters with SNP rs4291 and the I/D-polymorphism (sample 2) ACE activity ACE activity in unmedicated patients (N = 51) showed a nonsignificant (ONEWAY ANOVA: F 2,50 = 3.09, Abbreviations: HWE, Hardy-Weinberg equilibrium; MD, unipolar major depression (DSM-IV); PM, polymorphism. Controls (1) = matched controls for sample 1.
Controls (e) = epidemiologic control sample. Controls (2) = matched controls for sample 2. *P-value logistic regression sample 1 vs controls (e) (significant P-values bold). P = 0.055) trend to higher values in patients homozygous for the SNP rs4291 T-allele and lower activity in homozygous AA-carriers. After 2 weeks of antidepressant therapy patients homozygous for the Tallele showed significantly higher ACE activity than A-allele carriers (ONEWAY ANOVA: F 2,53 = 6.57, P = 0.003). Bonferroni corrected post hoc tests showed significant differences between TT-and AA-genotypes and TT-and AT-genotypes, respectively ( Figure 3) . Moreover, at both investigated time points ACE activity was significantly dependent from the genotype of the I/D-polymorphism (ONEWAY ANOVA after admission: F 2,51 = 8.14, P = 0.001, week 2: F 2,48 = 4.89, P = 0.012). The activity corresponded with the presence of the D-allele and reflected a gene dosing effect.
HPA-axis activity
Differences in cortisol response during the combined Dex/CRH test between the various rs4291 genotypes in unmedicated patients (N = 77) are shown in Figure  4 . There were significant between-subject effects of rs4291 genotypes on cortisol response (F 2,76 = 3.08; P = 0.040). Patients homozygous for the T-allele showed a clear HPA system hyperactivity, whereas the cortisol response of A-allele carriers after hCRH stimulation was blunted. Analysis of the covariates age and gender detected a trend towards an influence of age (F 1,76 = 3.84; P = 0.054) but no influence of gender (F 2,76 = 0.007; P = 0.934). However, baseline cortisol levels, defined as the mean between 14 and 15 hours before CRH challenge as a covariate, affected HPA system activity significantly in that higher cortisol baseline levels yielded a higher induced response to CRH (F 1,76 = 227; P < 0.001). The I/Dpolymorphism as a between-subjects factor showed a nonsignificant trend towards a higher cortisol response in D-allele carriers (F 2,76 = 3.04; P = 0.054). The highest cortisol secretion was measured in D/D-, the lowest in I/I-genotypes.
Discussion
We investigated the association of variants of the ACE gene region with unipolar major depression, including a dense SNP mapping and the ACE I/D-polymorphism in two independent case/control samples. Significant associations with depression were identified for more than 10 SNPs, but after correction for multiple testing only two SNPs (rs4291 and rs4295) located in the promoter area and intron 1 of the ACE gene retained highly significant associations with major depression in our screening sample 1. In sample 2, the association of SNP rs4291 with unipolar major depression could be confirmed in spite of the reduced power of sample 2 due to the smaller sample size.
In our association analysis we observed that the genotype distribution of the most highly associated SNPs actually showed a significant deviation from HWE (DHW) in the healthy control groups from both the MPI and the LMU. DHW can be an indicator for genotyping error. We did not observe DHW in the other samples, including depressed patients in samples 1 and 2, and, most importantly, an epidemiological control sample genotyped with identical methods and primers (results, Table 2 ), ruling out a general problem with these specific genotyping assays. In addition, cases and healthy controls of sample 1 and 2 were genotyped on the same experimental day using the same enzyme and primer master-mix. Assays for cases and control were also run in part on the same 384-well plate. Replication of rs4291 and rs4295 genotypes in the healthy control group of sample 1 yielded a 100% concordance of genotypes. This would rule out any problems with the genotyping assays run on a specific experimental day or specific assay plate. We thus feel confident that our results are not based on genotyping errors. This deviation is also unlikely to be due to hidden population structure since our study was restricted to Caucasians with 88% of people originating from Germany. In addition, analysis of 100 unlinked markers genotyped in control sample 1 did not yield any evidence for a systemic deviation from HWE in this sample.
Apart from genotyping errors DHW in a case/ control study may also occur as a consequence of a positive association. Wittke-Thompson in her theoretical investigation showed that under certain conditions DHW in controls is to be expected in association studies. 27 In that case, the direction of differences between expected and observed genotype frequencies in cases and controls should be opposite, which is what we observe for the rare allele homozygotes for rs4291 and rs4295 when compared to the genotype frequency in the epidemiological control sample (Table 2) . Furthermore, the deviations are determined by the population susceptibility-allele frequency and relative risks of the genotypes at the susceptibility locus. 27 DHW is expected to be greatest at the disease susceptibility locus itself, since this is the factor that determines the selection criterion. Loci that are phenotypically neutral but are associated with the disease-susceptibility locus, such as genetic markers in LD with the disease-susceptibility locus, also experience disproportionate genotype selection. Figure 4 Significant influence of SNP rs4291 on the combined Dex/CRH-test (sample 2): patients homozygous for the T-allele showed a clear HPA system hyperactivity, whereas the cortisol secretion of A-allele carriers after hCRH stimulation was blunted.
Moreover, Feder et al. 31 have suggested that fine localization of a disease-susceptibility locus could be accomplished by use of DHW among affected individuals. In this light, DHW in our control sample strengthens the observed association and in fact testing this hypothesis using the method described by Wittke-Thompson et al., 27 showed that our data are compatible with a recessive mode of action of ACE that could lead to deviations in HWE. The fact that we observed deviation from HWE in two control samples in which we selected against mood disorders but not in an epidemiological control sample suggests that the genotype conformation found in these samples may be protective from mood disorder.
The lack of association for ACE SNPs when comparing patients to the epidemiological control group (Table 2) likely stems from the high prevalence of mood disorders in the general population (up to 12-20% for depression alone 32 ) and reflects a general problem using such controls for disorders with a high prevalence in the general population. The use of case/ control samples may have more power to detect genetic associations for these common disorders. In addition, both control samples possibly also showed a more healthy cardiovascular profile than the general population. For control sample 2 medical illness and the concomitant use of antihypertensive medication such as ACE inhibitors or angiotensin receptor blockers served as an exclusion criterion. In sample 1 the selection against depression and anxiety was accompanied by a lower incidence of hypertension and stroke compared to the patient group. ACE polymorphisms have been associated with cardiovascular disease as well as longevity. 33 It is therefore not surprising that some of the SNPs in a gene associated with both depression and cardiovascular disease would be out of HWE in a group of individuals with a low prevalence of both disorders.
The analysis of the LD pattern of the ACE gene region revealed that these SNPs are located within an LD block containing the ACE gene but not the neighboring genes, indicating that the observed associations can be attributed to this gene. According to the promoter prediction analysis program TESS, 34 the A-allele of rs4291 encodes binding sites for YingYang1 35 while the T-allele encodes binding sites for Ying-Yang1 factor, 35 the glucocorticoid responsive element described in the mouse ras gene 36 and a TATA-box binding protein. It is thus possible that rs4291 has functional consequences for ACE gene transcription regulation. It is, however, not clear whether rs4291 really is the causal variant, as it is located within a large block of strong LD (D 0 > 0.85) and therefore might just be in LD with a hitherto untyped causal polymorphism. The region surrounding rs4291 is depicted more in detail in Figure 5 .
All previous association studies for ACE and affective disorders conducted by genotyping only the ACE I/D-polymorphism have yielded inconsistent results. 10, 8, 11, 12, 13 Rs4291, the promoter SNP that was significantly associated with unipolar depression in appears to be the better measure for investigating population history and r 2 to be more useful in disease mapping. 29 If we hypothesize that the causal variant responsible for the association of ACE with unipolar depression is rs4291 or located in closer proximity to it, we would expect that studies using a polymorphism that is not in complete LD with this variant, such as the I/D-polymorphism, have less power to detect a significant association. The required sample size to detect an association increases with decreasing LD from the causal variant. Previous studies investigating the association of the ACE gene using the I/Dpolymorphism have therefore been hampered by smaller sample sizes 8, 12, 13 as well as less homogeneous patient samples.
12 Sample 1 showed a trend for an association with the I/D-polymorphism which was not replicated in sample 2, possibly due to the smaller size of this sample.
The ACE I/D-polymorphism has been shown to influence ACE serum concentrations. 3, 4 This finding could be replicated in our sample. As rs4291 is in LD with this polymorphism, it might also be related to functional changes or even be responsible for them. We first analyzed the influence of rs4291 genotypes on ACE enzyme activity (sample 2) and found an association between rs4291 genotype and ACE enzyme serum activity, reminiscent of a gene dose effect (Figure 3) . The highest ACE activities were found in patients homozygous for the T-allele, the lowest in patients homozygous for the A-allele. Heterozygous patients showed intermediate enzyme activity. These differences were nonsignificant trends at baseline before antidepressant treatment and became significant after 2 weeks of treatment. As we did not investigate ACE activity in the entire sample, the smaller sample size might be responsible for the nonsignificant differences at the first measurement before treatment. Nevertheless, our results show that, similar to the functional ACE I/D-polymorphism, rs4291 influences ACE serum activity. Whether the ACE I/D-polymorphism represents this effect or the SNP variants within the promoter region of the ACE gene contribute to this functional consequence cannot be determined using association data only. Functional in vitro assays will be required to clarify this issue. We then investigated the influence of rs4291 genotype on HPA-axis activity under baseline conditions in medication-free patients (sample 2) using the combined Dex/CRH test. So far, this test appears to be the most sensitive tool to detect depression-related HPA system dysregulation. 37 A test sensitivity of 80-90% has been shown in depressed patients across numerous studies. 38 We found an rs4291 genotype-dependent cortisol release during the combined Dex/CRH test. Both significantly higher baseline cortisol levelsbefore CRH challenge and higher cortisol secretion after CRH stimulation were seen in patients homozygous for the T-allele (Figure 4) . A similar, but nonsignificant trend could be observed with regard to the ACE I/ D-polymorphism. Higher ACE concentrations 3,4 with a higher capability for the hydrolysis of angiotensin I into AT-II have been demonstrated in ACE I/Dpolymorphism D-allele carriers 39 who show functional similarities in HPA-axis overdrive with our SNP rs4291 T-allele carriers. Patients homozygous for the T-allele had higher stimulated cortisol concentrations than patients with the two other genotypes. Thus, during depression there appears to be an interrelationship not only between the functional ACE I/D-polymorphism and the HPA-axis overdrive 7 but also between SNP rs4291 variants and the HPAaxis. As several animal studies have demonstrated a strong interrelationship between intracerebral AT-II and the secretion of pituitary hormones, such an interrelation may also influence the susceptibility to develop a depressive disorder. In rats, AT-II may stimulate CRH 40, 41 and vasopressin (AVP). 40 On the other hand, AT-II may also regulate the expression of CRH. 5 In addition it has been shown that an inhibition of ACE activity or a blockade of AT-II type 1 (AT(1)) receptors attenuates HPA-axis reactivity possibly due to a reduced pituitary sensitivity to CRH or a downregulation of the hypothalamic CRH expression. 42 Investigations in humans showed similar relationships in healthy controls and hypertensive patients receiving ACE inhibitors 43 or AT(1) receptor blockers. 44 In healthy humans, AT-II has stimulating effects on ACTH secretion, 41 while AT(1) receptor blockade reduces the sensitivity of the adrenals to ACTH in the zona glomerulosa. 44 These HPA-axisstimulating properties of higher AT-II levels are in line with our study. As both the administration of ACE inhibitors and AT(1) receptor blockers were exclusion criteria, and the investigation was performed in unmedicated patients, a pharmacological influence on HPA-axis activity, albeit not existent for most antidepressants, can be ruled out in our study. 45 Another explanation could be a direct modulation of cortisol secretion by an enhanced sensitivity of the adrenals to ACTH in patients with high AT-II levels.
The association of ACE gene variants with unipolar MDD is possibly confounded by the association with coronary heart disease. The D-allele of the ACE I/Dpolymorphism has been associated with arterial hypertension 46, 47 and the risk of left ventricular hypertrophy, 48 and may be associated with the risk of coronary artery disease. 49 In addition, depression appears to be a risk factor for both morbidity and mortality of coronary heart disease, 50, 51 and significantly increases mortality after survival of a myocardial infarction. 52, 53, 54 On the other hand, depression is also a predisposing factor for coronary heart disease. 15, 55 Furthermore, central stress regulation systems like the HPA system seem to play a crucial role in influencing morbidity and mortality of cardiovascular diseases. 56 To rule out coronary heart disease as a confounder in our association we controlled for a series of factors related to coronary heart disease. We found that patients with major depression are more likely to have high blood pressure or to have suffered a stroke, which is in accordance with previous reports. 57 The inclusion of these variables, however, did not change the association of ACE polymorphisms with unipolar depression, suggesting that ACE variants independently contribute to the susceptibility for unipolar depression. Nevertheless, we also observed a significant association of rs4291 with coronary heart disease (P < 0.05). The described HPA-axis alteration with the highest cortisol stimulation observed in SNP rs4291 T-allele carriers and the highest risk for both cardiovascular diseases and unipolar depression may therefore represent a potential pathophysiologic link between the coincidence and comorbidities of higher cardiovascular risks, cardiovascular disease and depression. To obtain more clarity concerning these interdependencies, further cardiovascular risk factors and their association with genetic variants of the ACE gene have to be investigated in patients suffering from major depression. Moreover, interdependencies between antihypertensive medication such as ACE inhibitors and depression should be investigated systematically. This seems to be of importance because antidepressant effects of the ACE inhibitor captopril are reported in case reports 58 and openlabeled studies. 59 On the other hand, animal experiments revealed no indication for antidepressant effects, 60 and statistical investigations in the prescription disequilibrium of antidepressants and ACE inhibitors even suggested possible depressiogenic effects of ACE inhibitors. 61 Our systematic investigation of ACE gene variants in patients suffering from unipolar MDD confirms an association of the ACE gene with this disease. The T-allele of the SNP rs4291 seems to be a susceptibility factor for developing a major depressive episode as well as a dysfunctional HPA-axis regulation and also determines ACE activity. Homozygous T-allele carriers apparently are at the highest risk for development of a typical MDD including marked hypercortisolism. Rs4291 genotype seems to be superior in predicting the risk for unipolar major depression in comparison to the previously published variants of the ACE I/D-polymorphism, although both polymorphisms are in LD. In conclusion, our data suggest that variants in the ACE gene might provide a common link between the risk of developing a depressive episode, HPA system regulation and cardiovascular disease.
